Cell Type Solutions
The Catalent Cell Therapy team brings close to a decade of experience in the development and manufacture of autologous and allogeneic therapies. Our technology experts have worked with a wide selection of immune and stem cells and have consistently enabled our clients to progress their therapies to the market faster. As cell therapy technologies are advancing from autologous to allogeneic manufacturing, from single modifications to genome-editing, or from donor-sourced cells to iPSC-derived cells, Catalent is making investments to stay at the forefront of manufacturability of these innovative technologies. We have a dedicated innovation team that is working across the entire cell and gene portfolio to bring new technologies, processes, equipment and assays into the development and manufacturing process. Everyting we do at Catalent is about scaling quickly, effectively, and safely.
Catalent has been making significant investments in expanding capacity, innovation and strategic partnerships to mitigate the growing market gap of available capacity and expertise in commercial manufacturing of cell therapies. We are the partner of choice with an integrated, end-to-end vision of commercial manufacturing supply chain enabling to overcome complexities associated with autologous and allogeneic cell therapy manufacturing.